Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.120 +0.050 (+1.23%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference ↗

September 20, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing...

Via MarketBeat

Topics Artificial Intelligence

2 Beaten-Down Stocks to Avoid Right Now ↗

September 08, 2026

Don't catch a falling knife.

Via The Motley Fool

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates ↗

August 17, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and...

Via MarketBeat

Topics Artificial Intelligence

Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss ↗

May 06, 2026

Via Chartmill

Recursion Pharmaceuticals (NASDAQ:RXRX) Soars on Q4 Earnings Beat ↗

February 25, 2026

Via Chartmill

Recursion (RXRX) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Via The Motley Fool

Topics Artificial Intelligence Earnings

Recursion Pharmaceuticals Q2 Earnings Call Highlights ↗

August 05, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense...

Via MarketBeat

Topics Artificial Intelligence Earnings

3 Stocks With the Most Upside by the End of 2026 ↗

July 30, 2026

Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.

Via The Motley Fool

Topics Workforce

Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? ↗

July 14, 2026

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Via The Motley Fool

Topics Artificial Intelligence ETFs

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

July 11, 2026

Your hard-earned money would be better spent elsewhere.

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

July 05, 2026

Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.

Via The Motley Fool

Topics ETFs

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗

July 04, 2026

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.

Via The Motley Fool

Topics Artificial Intelligence

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? ↗

July 03, 2026

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Via The Motley Fool

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 30, 2026

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Via The Motley Fool

Topics Artificial Intelligence

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market ↗

June 27, 2026

Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting.

Via The Motley Fool

Topics Artificial Intelligence

2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗

June 26, 2026

These aren't for the faint of heart.

Via The Motley Fool

Topics Artificial Intelligence

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 02, 2026

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Via The Motley Fool

Topics Artificial Intelligence

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗

May 25, 2026

The stock looks cheap, but appearances can be deceiving.

Via The Motley Fool

Topics Artificial Intelligence

A Deep Dive Into NVIDIA’s Latest Portfolio Moves ↗

May 19, 2026

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

Via MarketBeat

Topics Artificial Intelligence Economy Regulatory Compliance

3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗

May 08, 2026

The old healthcare model is breaking down.

Via The Motley Fool

Topics Artificial Intelligence

Recursion (RXRX) Q1 2026 Earnings Transcript ↗

May 07, 2026

Recursion (RXRX) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Artificial Intelligence

Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine

April 06, 2026

In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...

Via MarketMinute

Topics Artificial Intelligence

1 Beaten-Down AI Stock to Buy and 1 to Avoid ↗

April 01, 2026

One of these is not like the other.

Via The Motley Fool

Topics Artificial Intelligence

2 AI Healthcare Stocks to Buy Right Now ↗

March 31, 2026

The convergence of two already fantastic industries is creating an incredible opportunity.

Via The Motley Fool

Topics Artificial Intelligence

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 ↗

March 22, 2026

The sweeping correction that most of these stocks have suffered was not only predictable, but it also reliably precedes a better-supported recovery.

Via The Motley Fool

Topics Artificial Intelligence

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years. ↗

March 21, 2026

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

Via The Motley Fool

Topics Artificial Intelligence

Can This AI Stock Bounce Back in 2026? ↗

March 08, 2026

It's not looking too good for the biotech.

Via The Motley Fool

Topics Animal Testing Artificial Intelligence

Recursion (RXRX) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Recursion (RXRX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Artificial Intelligence Earnings

What's Behind The Jump In Recursion Pharmaceuticals Stock? ↗

February 25, 2026

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell.

Via Benzinga

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗

February 25, 2026

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Via Stocktwits

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.